Lin C C, Kim H K, Marco A, Radwanski E, Symchowicz S
Antimicrob Agents Chemother. 1986 May;29(5):753-6. doi: 10.1128/AAC.29.5.753.
The pharmacokinetics and metabolism of [14C]rosaramicin were studied in dogs after intravenous (i.v.; 10 mg/kg [bodyweight]) and oral (25 mg/kg) administration. After i.v. administration, rosaramicin levels in plasma declined rapidly, with half-lives of 0.22 h for the distribution phase and 0.97 h for the elimination phase. The apparent volume of distribution was 3.43 liters/kg, and the total body clearance was 106 mg/min . kg, indicating extensive distribution in tissue or metabolism or both. The absorption of oral solution was 58%, and the absolute bioavailability of rosaramicin was 35%. The plasma area under the curve of unchanged rosaramicin was only 5% that of total radioactivity after oral administration and 8% after i.v. administration, indicating extensive metabolism of the drug. The total radioactivity excreted in urine accounted for only 24% of the i.v. dose and 17% of the oral dose. Fecal radioactivity accounted for 71% of the i.v. dose and 68% of the oral dose. Several metabolites were observed in the plasma and urine. The amount of unchanged rosaramicin in urine (1 to 2% of the dose) was quite small after drug administration by either route.
在犬静脉注射(10毫克/千克[体重])和口服(25毫克/千克)[14C]罗沙米星后,对其药代动力学和代谢情况进行了研究。静脉注射后,血浆中罗沙米星水平迅速下降,分布相半衰期为0.22小时,消除相半衰期为0.97小时。表观分布容积为3.43升/千克,全身清除率为106毫克/分钟·千克,表明药物在组织中广泛分布或发生代谢或两者兼有。口服溶液的吸收率为58%,罗沙米星的绝对生物利用度为35%。口服给药后,未变化的罗沙米星的血浆曲线下面积仅为总放射性的5%,静脉注射后为8%,表明该药物发生广泛代谢。尿中排泄的总放射性仅占静脉注射剂量的24%和口服剂量的17%。粪便放射性占静脉注射剂量的71%和口服剂量的68%。在血浆和尿液中观察到几种代谢物。无论通过哪种途径给药,给药后尿中未变化的罗沙米星量(占剂量的1%至2%)都相当少。